(NASDAQ: ADMA) Adma Biologics's forecast annual revenue growth rate of 13.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.
Adma Biologics's revenue in 2026 is $512,275,000.On average, 6 Wall Street analysts forecast ADMA's revenue for 2026 to be $122,311,314,208, with the lowest ADMA revenue forecast at $116,480,992,987, and the highest ADMA revenue forecast at $127,711,584,842. On average, 6 Wall Street analysts forecast ADMA's revenue for 2027 to be $143,829,522,415, with the lowest ADMA revenue forecast at $131,687,312,912, and the highest ADMA revenue forecast at $157,976,394,804.
In 2028, ADMA is forecast to generate $166,593,085,444 in revenue, with the lowest revenue forecast at $145,551,964,604 and the highest revenue forecast at $192,279,648,546.